Deals, Development and Manufacturing

The company reported that phase I data show approximately 40% of patients remained cancer-free at 10 years, while 2 phase 2 trials are ongoing.

Made Scientific and Pluristyx will integrate iPSC starting materials with CDMO services for cell therapy development.

CytomX and Regeneron aim to deepen their joint effort to develop protease-activated bispecific immunotherapies designed to improve tumor selectivity and widen the therapeutic window in solid tumors.

Hansa Biopharma’s licensing agreement with SERB will support expanded commercialization of imlifidase (Idefirix) for highly sensitized kidney transplant patients across Europe and MENA.

For ATMP developers, the greatest barrier to commercialization is often not scientific discovery or funding, but the challenge of translating research-stage processes into reproducible, GMP-compliant manufacturing without compromising the therapy itself.

Bristol Myers Squibb and Hengrui Pharma’s strategic collaboration supports development of investigational oncology, hematology, and immunology therapies targeting unmet patient needs.

GSK’s licensing agreement for SiranBio’s ALK7-targeting siRNA candidate expands development efforts aimed at reducing cardiometabolic risk in chronic inflammatory diseases.

Ligand’s acquisition of XOMA Royalty expands the royalty model, supporting late-stage drug development and diversifying access to oncology and rare disease therapies.

Novo Nordisk intends to apply advanced AI to analyze complex data, improve target identification, and accelerate development of therapies for chronic diseases

In the collaboration, Regeneron and Telix will combine antibodies with targeted radiation to improve tumor selectivity as they aim to enable more precise treatment and response monitoring in oncology.

Through collaboration, Imagene AI and Daiichi Sankyo will apply multimodal AI to improve biomarker discovery with the goals of advancing precision oncology and enhancing clinical trial success rates.

The acquisition aims to advance next-gen ADCs that target NaPi2b and 5T4 and that show early clinical activity in solid tumors, which highlight advances in precision payload delivery and durability.

For World Health Day 2026, we examine how today’s global partnerships are increasingly aimed at translating research into real-world care and scalable therapies while expanding access worldwide and utilizing AI-driven oncology tools.

In a new collaboration, Tempus and Daiichi Sankyo will apply AI-driven biomarker discovery to improve ADC patient selection with the aim of advancing precision strategies in competitive oncology pipelines.

With the license, Sanofi gains Kali Therapeutics’ tri-specific T-cell engager pipeline candidate, KT501, which targets B cell-mediated autoimmune diseases.

The company is targeting the $3 billion pancreatic cancer market with its lead proenzyme therapy candidate, PRP, which is supported by strong preclinical tumor inhibition data and for which a PK assay will be developed and validated.

Under the partnership, INOVIO and Akeso will evaluate DNA-encoded tumor antigen priming plus PD-1/CTLA-4 bispecific blockade in an adaptive Phase II trial for glioblastoma.

Persistent medicines shortages across the EU reflect structural supply chain vulnerabilities, fragmented national regulations, and concentrated API sourcing, increasing regulatory risk and financial exposure for marketing authorization holders while directly impacting patient access and continuity of care.

Under the collaboration, Merck and Mayo Clinic will integrate multimodal clinical and genomic datasets with AI models to enhance target biology insights and translational decision-making.

Pharma organizations that approach automation as both a technical and an inventory readiness challenge are best positioned to realize lasting operational benefits.

Integrated CDMO networks streamline complex drug development across advanced modalities like ADCs.

The Eisai–Henlius partnership expands Japan’s access to a differentiated PD-1 antibody, highlighting cross-border oncology deals targeting high unmet need.

A new Cellares–Stanford collaboration aims to demonstrate how automated platforms could standardize gene-edited stem cell manufacturing and accelerate clinical translation.

The SK bioscience–Gates MRI agreement highlights how scalable mAbs could broaden infant RSV prevention beyond high-income markets.

AdvanCell and 48Hour Discovery align peptide discovery with a Lead-212 infrastructure to build a durable targeted alpha therapy pipeline aimed at oncology markets.